According to the official website of the State Food and Drug Administration, on the morning of September 27, the establishment of the 12th Pharmacopoeia Committee and the first plenary meeting were held in Beijing, and the preparation of the 2025 edition of the Chinese Pharmacopoeia was fully launched. The Pharmacopoeia Committee is the most authoritative technical organization in the field of pharmacy in China, which undertakes the mission of formulating national drug standards. Jiao Hong, director of the State Food and Drug Administration, pointed out that drug standards are extremely important for drug regulation. We should fully understand that drug standards are an important guarantee for promoting the high-quality development of the pharmaceutical industry. We should balance the relationship between keeping the bottom line and pursuing the top line, build and improve a drug standard system that meets China's development reality and international prevailing requirements, and promote China's leap from a big pharmaceutical country to a strong pharmaceutical country. Jiao Hong pointed out that we should resolutely implement the decisions and arrangements of the CPC Central Committee and the State Council, comprehensively strengthen capacity building, and promote drug standards and high-quality development of the pharmaceutical industry in accordance with the requirements of the Implementation Opinions on Comprehensively Strengthening Drug Regulatory Capacity Building and the "Fourteenth Five Year Plan" National Drug Safety and Promoting High Quality Development Plan. Jiao Hong made arrangements for the next phase of drug standard work. The first is to strengthen the planning and effectively prepare the 2025 edition of the Chinese Pharmacopoeia. We should constantly improve the scientificity, progressiveness, practicability and standardization of the Pharmacopoeia, and strengthen the guiding role of the Chinese pharmacopoeia in ensuring the safety, effectiveness and controllable quality of drugs; Implement the concept of drug life-cycle management, actively explore the development strategy of drug standards, give full play to the important technical support role of drug standards for drug supervision, and promote the improvement of regulatory capacity. Second, lay a solid foundation to promote the basic work of drug standards. It is necessary to improve the legal and regulatory system of drug standards, improve the working mechanism of drug standards, optimize the working procedures of drug standards, strengthen the construction of drug standards system, and improve the management ability of drug standards. The third is to explore and innovate, earnestly strengthen the informatization construction of drug standards, promote the digitalization of pharmacopoeia, and continuously improve the quality and efficiency of drug standard management. Fourth, open sharing and promote international standards coordination. We should expand our international vision, deeply participate in international coordination, and enhance the international influence of our pharmacopoeia. (Outlook New Times)